The prevention and treatment of diseases have been revolutionised by medications and vaccines. Medicinal medicines may have side effects in addition to their advantages, some of which may be unwelcome and/or unexpected. Pharmacovigilance is the study and practise concerned with the identification, evaluation, comprehension, and avoidance of side effects or any other issue with drugs or vaccines.
Before being approved for use, all medications and vaccines go through extensive clinical trials to test their safety and efficacy. However, the clinical trial procedure entails observing these goods for a brief period of time in a relatively small number of carefully chosen people. Certain adverse effects might not become apparent until after these medications have been taken for a long time and by a diverse population, including those with other concurrent conditions. Adverse event reporting is the activity that is most frequently connected to Pharmacovigilance (PV) and that uses a large amount of resources for drug regulatory authorities (or comparable governmental organisations) and drug safety departments in pharmaceutical corporations. Receiving, sorting, entering data, evaluating it, distributing it, reporting (if necessary), and archiving adverse event (AE) data and documentation are all part of AE reporting. Initiated reports from patient support programmes, reports from clinical or Pharmacovigilance, reports from literature sources, reports from the media (including social media and websites), and reports submitted directly to drug regulatory agencies are all possible sources of AE reports. Determining what qualifies as an individual case safety report is one of the core tenets of adverse event reporting. It's crucial to check whether the "four ingredients" of a legitimate individual case safety report an identifiable patient, an identifiable reporter, a suspect drug, and an adverse event are present during the triage phase of a possible adverse event. The case is not a legitimate individual case safety report if one or more of these four components is missing. There are no exceptions to this rule, yet there might be some situations where a decision must be made. For instance, the definition of "identified" may not necessarily be precise. Even when the patient is not clearly identified, the Pharmacovigilance is still valid if a doctor says they have a patient X taking medicine Y who suffered Z (an AE), but they won't give any more details. This is true because the reporter is recognisable to the doctor as a genuine person and has first-hand knowledge of the patient. Identification is crucial to avoid multiple reporting of the same information. The other three elements also fall under the definition of identifiability. It is not unheard of for bogus adverse event "cases" to be reported to a firm by an anonymous person (or on behalf of an anonymous patient, unhappy employee, or former employee) who is attempting to harm the company's reputation or a company's product, despite the fact that this is uncommon. The source of the report should be determined in these instances, as well as all others (if possible). However, anonymous reporting is equally crucial because not all nations offer whistleblower protection. Generally speaking, the substance must also be mentioned by name. Be aware that medications are Pharmacovigilance under a variety of names in various nations and areas of the world. Additionally, there are other generics that could be misidentified.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2023
Categories
All
|